EYE ON CHINA
Abstract
Epigenomics and BioChain enter into broad strategic collaboration in China.
China Sunergy's Head of Research wins 2013 ACAA/IELTS Australia China Alumni Awards.
WuXi PharmaTech enters agreement for patient-derived xenograft models with Mayo Clinic's Center for individualized medicine.
Merck enters into further global co-development and commercialization agreement for PARP inhibitor with Chinese R&D company BeiGene.
Creganna-Tactx Medical opens office in China.
Honeywell to modernize petrochemical plants in China.
WuXi PharmaTech to partner with Pharmacyclics.
Novozymes and M&G Chemicals to collaborate on biomass-based plastics in China.
Catalent's Clinical Trial Supply Facility in Shanghai, China opens for business.
Shanghai Institute of Materia Medica and Crown Bioscience to develop mouse clinical center and PDX and Translational Oncology Platform.
